Peptides and related molecules that bind to TALL-1
    4.
    发明授权
    Peptides and related molecules that bind to TALL-1 有权
    结合TALL-1的肽和相关分子

    公开(公告)号:US07737111B2

    公开(公告)日:2010-06-15

    申请号:US11272521

    申请日:2005-11-10

    IPC分类号: A61K38/10

    摘要: The present invention concerns therapeutic agents that modulate the activity of TALL-1. In accordance with the present invention, modulators of TALL-1 may comprise an amino acid sequence Dz2Lz4 wherein z2 is an amino acid residue and z4 is threonyl or isoleucyl. Exemplary molecules comprise a sequence of the formulae (SEQ. ID. NO:100) a1a2a3CDa6La8a9a10Ca12a13a14, (SEQ. ID. NO:104) b1b2b3Cb5b6Db8Lb10b11b12b13b14Cb16b17b18 (SEQ. ID. NO:105) c1c2c3Cc5Dc7Lc9c10c11c12c13c14Cc16c17c18 (SEQ. ID. NO:106) d1d2d3Cd5d6d7WDd10Ld13d14d15Cd16d17d18 (SEQ. ID. NO:107) e1e2e3Ce5e6e7De9Le11Ke13Ce15e16e17e18 (SEQ. ID NO:109) f1f2f3Kf5Df7Lf9f10Qf12f13f14 wherein the substituents are as defined in the specification. The invention further comprises compositions of matter of the formula (X1)a—V1—(X2)b wherein V1 is a vehicle that is covalently attached to one or more of the above TALL-1 modulating compositions of matter. The vehicle and the TALL-1 modulating composition of matter may be linked through the N- or C-terminus of the TALL-1 modulating portion. The preferred vehicle is an Fc domain, and the preferred Fc domain is an IgG Fc domain.

    摘要翻译: 本发明涉及调节TALL-1活性的治疗剂。 根据本发明,TALL-1的调节剂可以包含氨基酸序列Dz2Lz4,其中z2是氨基酸残基,z4是苏氨酰基或异亮氨酰基。 示例性分子包括下式的一个序列(SEQ。ID NO:100)a1a2a3CDa6La8a9a10Ca12a13a14,(SEQ ID NO:104)b1b2b3Cb5b6Db8Lb10b11b12b13b14Cb16b17b18(SEQ ID。NO:105)c1c2c3Cc5Dc7Lc9c10c11c12c13c14Cc16c17c18(SEQ ID。NO:106)d1d2d3Cd5d6d7WDd10Ld13d14d15Cd16d17d18( SEQ ID NO:107)e1e2e3Ce5e6e7De9Le11Ke13Ce15e16e17e18(SEQ ID NO:109)f1f2f3Kf5Df7Lf9f10Qf12f13f14其中取代基如说明书中所定义。 本发明还包括式(X1)a-V1-(X2)b的物质的组合物,其中V1是共价连接到一种或多种上述TALL-1调节组合物的载体。 载体和TALL-1调节组合物可以通过TALL-1调节部分的N末端或C末端连接。 优选的载体是Fc结构域,优选的Fc结构域是IgG Fc结构域。

    Peptides and related molecules that bind to TALL-1

    公开(公告)号:US20060135431A1

    公开(公告)日:2006-06-22

    申请号:US11272521

    申请日:2005-11-10

    IPC分类号: A61K38/10 C07K7/08

    摘要: The present invention concerns therapeutic agents that modulate the activity of TALL-1. In accordance with the present invention, modulators of TALL-1 may comprise an amino acid sequence Dz2Lz4 wherein z2 is an amino acid residue and z4 is threonyl or isoleucyl. Exemplary molecules comprise a sequence of the formulae (SEQ. ID. NO:100) a1a2a3CDa6La8a9a10Ca12a13a14, (SEQ. ID. NO:104) b1b2b3Cb5b6Db8Lb10b11b12b13b14Cb16b17b18 (SEQ. ID. NO:105) c1c2c3Cc5Dc7Lc9c10c11c12c13c14Cc16c17c18 (SEQ. ID. NO:106) d1d2d3Cd5d6d7WDd10Ld13d14d15Cd16d17d18 (SEQ. ID. NO:107) e1e2e3Ce5e6e7De9Le11Ke13Ce15e16e17e18 (SEQ. ID NO:109) f1f2f3Kf5Df7Lf9f10Qf12f13f14 wherein the substituents are as defined in the specification. The invention further comprises compositions of matter of the formula (X1)a-V1-(X2)b wherein V1 is a vehicle that is covalently attached to one or more of the above TALL-1 modulating compositions of matter. The vehicle and the TALL-1 modulating composition of matter may be linked through the N- or C-terminus of the TALL-1 modulating portion. The preferred vehicle is an Fc domain, and the preferred Fc domain is an IgG Fc domain.